OTHER BLOGS

<strong>Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI<sup>®</sup>(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma</strong>

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI..

Jan 27, 2023

<strong>Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC</strong>

Legend Biotech Announces Notification of Delinquency from The Nasda..

Jan 10, 2023

<strong>Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference</strong>

Legend Biotech to Participate in the 41st Annual JP Morgan Healthca..

Jan 04, 2023

<strong>Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China</strong>

Legend Biotech Announces Acceptance of Its New Drug Application for..

Jan 02, 2023

<strong>Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer</strong>

Legend Biotech Announces FDA Clearance of IND Application for LB210..

Nov 21, 2022

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.